Key clinical point: Among patients with acute myeloid leukemia (AML) who underwent first allogeneic hematopoietic stem cell transplantation (allo-HSCT), children showed superior clinical outcomes compared to adolescents and postadolescents (APA) and young adults.
Major finding: At 2 years, the cumulative incidence of chronic graft-versus-host disease ( P < .0001), relapse ( P = .0254), and nonrelapse mortality ( P < .0001) were significantly lower, and overall survival ( P = .0009) and event-free survival ( P = .0186) were higher in children compared to APA and young adult patients with AML.
Study details: Findings are from a retrospective analysis of children (age 0-14 years; n = 564), APA patients (age 15-25 years; n = 647), and young adults (age 26-40 years; n = 1,434) with AML who received a first allo-HSCT in the first or further remission or in refractory state.
Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.
Source: Pochon C et al. J Cancer Res Clin Oncol. 2021 Sep 4. doi: 10.1007/s00432-021-03761-w .